106.18

2.45% -2.67

Pre-market: 106.30 0.12 +0.11%

Moderna Inc (MRNA)

Overview News Price History Option Chain Why MRNA Down? Discussions Forecast

Moderna Inc stock is currently priced at $106.18, with a 24-hour trading volume of 2.71M. It has seen a -2.45% decreased in the last 24 hours and a -3.81% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $108.9 pivot point. If it approaches the $104.3 support level, significant changes may occur.

Previous Close:

$108.85

Open:

$107.43

24h Volume:

2.71M

Market Cap:

$40.65B

Revenue:

$6.75B

Net Income/Loss:

$-4.71B

P/E Ratio:

-11.36

EPS:

-9.35

Net Cash Flow:

$-3.83B

1W Performance:

+4.10%

1M Performance:

-3.81%

6M Performance:

+38.33%

1Y Performance:

-21.29%

1D Range:

$103.52

$108.23

52W Range:

$62.55

$142.79

Moderna Inc Stock (MRNA) Company Profile

Name

Moderna Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

617-714-6500

Address

200 Technology Square, Cambridge

Employee

680

Twitter

@moderna_tx

Next Earnings Date

2024-05-06

Latest SEC Filings

MRNA's Discussions on Twitter

Moderna Inc Stock (MRNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-02-24	Upgrade	Oppenheimer	Perform → Outperform
Nov-29-23	Initiated	Canaccord Genuity	Hold
Nov-03-23	Upgrade	HSBC Securities	Reduce → Hold
Nov-02-23	Downgrade	Deutsche Bank	Hold → Sell
Aug-04-23	Downgrade	TD Cowen	Outperform → Market Perform
Aug-03-23	Downgrade	Deutsche Bank	Buy → Hold
Jul-24-23	Initiated	William Blair	Mkt Perform
Jul-14-23	Initiated	HSBC Securities	Reduce
Jun-26-23	Upgrade	UBS	Neutral → Buy
Apr-26-23	Initiated	Guggenheim	Neutral
Mar-13-23	Upgrade	TD Cowen	Market Perform → Outperform
Mar-02-23	Initiated	RBC Capital Mkts	Outperform
Feb-24-23	Downgrade	SVB Securities	Market Perform → Underperform
Dec-19-22	Upgrade	Jefferies	Hold → Buy
Dec-14-22	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-21-22	Upgrade	SVB Leerink	Underperform → Mkt Perform
Sep-08-22	Upgrade	Deutsche Bank	Hold → Buy
Feb-01-22	Upgrade	Redburn	Sell → Neutral
Jan-26-22	Upgrade	Deutsche Bank	Sell → Hold
Jan-21-22	Upgrade	BofA Securities	Underperform → Neutral
Jan-21-22	Initiated	UBS	Neutral
Dec-07-21	Initiated	Cowen	Market Perform
Nov-09-21	Initiated	Wolfe Research	Outperform
Oct-22-21	Initiated	Deutsche Bank	Sell
Oct-15-21	Upgrade	Piper Sandler	Neutral → Overweight
Aug-06-21	Downgrade	Oppenheimer	Outperform → Perform
Aug-06-21	Downgrade	Piper Sandler	Overweight → Neutral
Jul-15-21	Reiterated	Jefferies	Hold
Feb-01-21	Downgrade	BofA Securities	Neutral → Underperform
Dec-16-20	Downgrade	Jefferies	Buy → Hold
Dec-16-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-09-20	Downgrade	Needham	Buy → Hold
Nov-23-20	Initiated	Wells Fargo	Equal Weight
Nov-17-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
Sep-08-20	Downgrade	SVB Leerink	Mkt Perform → Underperform
Jul-23-20	Initiated	SVB Leerink	Mkt Perform
Jul-20-20	Downgrade	JP Morgan	Overweight → Neutral
Jul-13-20	Initiated	Jefferies	Buy
Jun-30-20	Initiated	Argus	Buy
Jun-08-20	Initiated	Barclays	Overweight
Apr-30-20	Initiated	BMO Capital Markets	Outperform
Mar-05-20	Downgrade	BofA/Merrill	Buy → Neutral
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-25-19	Initiated	ROTH Capital	Buy
Apr-05-19	Initiated	Chardan Capital Markets	Buy

View All

Moderna Inc Stock (MRNA) Latest News

Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research

Moderna Inc Stock (MRNA) Financials Data

Moderna Inc (MRNA) Revenue 2024

MRNA reported a revenue (TTM) of $6.75 billion for the quarter ending December 31, 2023, a -64.22% decline year-over-year.

Moderna Inc (MRNA) Net Income 2024

MRNA net income (TTM) was -$4.71 billion for the quarter ending December 31, 2023, a -156.37% decrease year-over-year.

Moderna Inc (MRNA) Cash Flow 2024

MRNA recorded a free cash flow (TTM) of -$3.83 billion for the quarter ending December 31, 2023, a -183.50% decrease year-over-year.

Moderna Inc (MRNA) Earnings per Share 2024

MRNA earnings per share (TTM) was -$12.41 for the quarter ending December 31, 2023, a -162.17% decline year-over-year.

Moderna Inc Stock (MRNA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
AFEYAN NOUBAR	Director	Apr 17 '24	Sale	103.38	15,000	1,550,703	2,056,931
Hoge Stephen	President	Apr 15 '24	Sale	105.02	15,000	1,575,300	1,486,241
AFEYAN NOUBAR	Director	Apr 10 '24	Sale	107.12	15,000	1,606,865	2,071,931
Mock James M	Chief Financial Officer	Apr 08 '24	Sale	101.93	705	71,859	5,048
AFEYAN NOUBAR	Director	Apr 03 '24	Sale	101.68	15,000	1,525,268	2,086,931
AFEYAN NOUBAR	Director	Mar 27 '24	Sale	109.06	15,000	1,635,864	2,101,931
AFEYAN NOUBAR	Director	Mar 20 '24	Sale	102.39	15,000	1,535,820	2,116,931
Hoge Stephen	President	Mar 15 '24	Sale	103.17	15,000	1,547,550	1,501,241
AFEYAN NOUBAR	Director	Mar 13 '24	Sale	108.54	15,000	1,628,031	2,131,931
Klinger Shannon Thyme	Chief Legal Officer	Mar 08 '24	Sale	99.05	544	53,884	9,267

Moderna, Inc. develops medicines based on messenger RNA (mRNA). Its pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.